

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 ⁽¹⁾)

(Text with EEA relevance)

(2023/C 220/03)

Decision granting an authorisation

Reference of the decision ⁽¹⁾	Date of decision	Substance name	Holder of the authorisation	Authorisation number	Authorised use	Date of expiry of review period	Reasons for the decision
C(2023) 3793	15 Jun 2023	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated ('4-tert-OPnEO') EC No.-; CAS No.-	LFB Biomedicaments, 3 avenue des Tropiques, ZA de Courtaboeuf, 91940, Les Ulis, France	REACH/23/19/0	Virus inactivation into the manufacture process of plasma-derived immunoglobulins	4 January 2028	In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

⁽¹⁾ The decision is available on the European Commission website at: [Authorisation \(europa.eu\)](http://authorisation.europa.eu).

⁽¹⁾ OJ L 396, 30.12.2006, p. 1.